EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacokinetics of polymyxin drugs in special populations

Aochao Xu, Zhaoyi Tan, Liuhan Dong, Beibei Liang, Zhijian Zhang, Yun Cai

Frontiers in Pharmacology · 03.07.2026 · 17

DOI: 10.3389/fphar.2026.1786482 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.07.2026. Verfasst von Aochao Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Phase I Clinical Trial Laboratory, The First Medical Center of the Chinese PLA General Hospital, Beijing, China. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rising incidence of multidrug-resistant Gram-negative infections has reaffirmed the importance of polymyxins (polymyxin B (PMB), colistin methanesulfonate (CMS), and colistin sulfate (CS)) as essential last-line treatments. This review assesses the pharmacokinetic (PK) and population pharmacokinetic (PopPK) data for polymyxins in special populations, aiming to establish agent-specific PK profiles and optimize dosing strategies. A total of 72 articles published between 2005 and 2025 were reviewed, with 36 focusing on the PK of PMB, 30 on CMS, and 6 on CS. PopPK analyses constituted the majority of the included studies. The review reveals that polymyxin pharmacokinetics exhibit substantial variability across special patient groups. Key findings include an increased voxlume of distribution in critically ill patients and the identification of renal function as a major covariate influencing polymyxins PK. Altered drug clearance in patients receiving renal replacement therapies (e.g., CRRT and IHD), while body weight influences distribution in obese individuals. Distinct PK profiles were also identified in patient populations such as pediatrics, the elderly, burn victims, those on ECMO, and those with cystic fibrosis. These conditions contribute to significant variability in drug exposure, underscoring the need for model-informed precision dosing (MIPD) combined with therapeutic drug monitoring (TDM) to optimize efficacy and minimize toxicity in these vulnerable populations.

Schlagwörter

Stichwörter der Autor:innen

colistin methanesulfonatecolistin sulfatepharmacokineticspolymyxin Bpopulation pharmacokinetics

Autor:innen und Institutionen

  • The Phase I Clinical Trial Laboratory, The First Medical Center of the Chinese PLA General Hospital, Beijing, China.
  • Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.

Zitieren

APA

Xu, A., Tan, Z., Dong, L., Liang, B., Zhang, Z., & Cai, Y. (2026). Pharmacokinetics of polymyxin drugs in special populations. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1786482

Vancouver

Xu A, Tan Z, Dong L, Liang B, Zhang Z, Cai Y. Pharmacokinetics of polymyxin drugs in special populations. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1786482

BibTeX
@article{Xu2026,
  author = {Xu, Aochao and Tan, Zhaoyi and Dong, Liuhan and Liang, Beibei and Zhang, Zhijian and Cai, Yun},
  title = {Pharmacokinetics of polymyxin drugs in special populations},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1786482}
}
Kostenlos starten →